Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q4 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET

Company Participants

Allison Wey - SVP, IR and Corporate Communications

Paul Edick - Chairman and CEO

Steve Pieper - CFO

Conference Call Participants

Roanna Ruiz - SVB Leerink

Vamil Divan - Mizuho Securities

David Amsellem - Piper Sandler


Hello everyone. And welcome to the Xeris Biopharma Fourth Quarter 2021 Financial Results Conference Call and Webcast. My name is Seth and I will be the operator for your call today. [Operator Instructions].

I will now hand the floor over to, Allison Wey, to begin. Please go ahead.

Allison Wey

Thank you. Good morning. And welcome to Xeris Biopharma's fourth quarter 2021 financial results and corporate update conference call and webcast. A press release with the company's fourth quarter and full year 2021 financial results was issued earlier this morning and can be found on our website.

We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, our CFO. Paul will provide opening remarks, Steve will provide details on our financial results and then we will open up the call for Q&A.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Xeris' business practices, Xeris' future expectations, plans, prospects, clinical approvals, commercialization, corporate strategy, performance, and the impact of COVID-19 on Xeris' business practices, which contain forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including the effect of uncertainties related to the COVID-19 pandemic on the U.S. and global markets, Xeris' business, financial condition, operations, clinical trials and third-party suppliers and manufacturers and other risk including those discussed in our filings

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.